As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s Clinical Endocrinology Update Steering Committee.


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.


The following steering committee members reported the following relevant financial relationship(s) that they or their spouse/partner have with commercial interests:

Whitney S. Goldner, MD (Incoming Chair): Primary Investigator for Astra Zeneca and Eisai. Site Primary Investigator for Roche. Husband is a nephrologist and is medical director for dialysis units for Davita.

Daniel H. Bessesen, MD: Serves on the data safety monitoring committee for Enteromedics Inc.

Sigridur Bjornsdottir, MD, PhD: Advisory Group for Amgen; Research Support for Shire; and Speaker for Mylan and Shire.

Kathleen M. Dungan, MD, MPH: Receives research funding from Novo Nordisk, Merck, Sanofi Aventis, GlaxoSmithKline. Is a consultant for Eli Lilly, GSK, Sanofi Aventis, Novo Nordisk, Mannkind. Receives royalties from Up to Date. Participated in development of CME Activities (indirectly funded by Pharma) from Novo Nordisk, Jansen, Merck, Astra Zeneca, Sanofi Aventis.

Monica Gadelha, MD, PhD: Advisory Board for Novartis and Ionis. Received lectures fee from Novartis and Ipsen. Is a principal investigator in clinical trials for Novartis and Ipsen. Received unrestricted research grants from Ipsen and Pfizer.

Serge A. Jabbour, MD (EBR Chair): Consultant and on Advisory boards for AstraZeneca, Eli Lilly & Janssen.

Priyathama Vellanki, MD: Consultant for Merck & Co. and Boehringer Ingelheim. Co-Investigator on a study at Emory University that is funded by Boehringer Ingelheim.

The following steering committee members reported no relevant financial relationships: Janet A. Schlechte, MD, Chair; Richard A. Bebb, MD; Ann E. Kearns, MD, PhD; Tim Korevaar, MD, PhD; Connie Baum Newman, MD; Camille E. Powe, MD; and Jennifer A. Sipos, MD.


The following presenting faculty reported the following relevant financial relationship(s) that they or their spouse/partner have with commercial interests:

Andrew Ahmann, MS, MD: Consultant for Dexcom, Novo, Sanofi, MannKind, Lilly. Receives research support from Medtronic, Dexcom.

Christel Marchand Aprigliano, MS: Speaker for Insulet and Roche Diabetes Care.

Richard Auchus, MD, PhD: Grant/Research/Clinical Trial Support: Strongbridge Biopharma; Novartis; Neurocrine Biosciences; Spurce Biosciences; Diurnal, LTD. Consultant/Advisory Boards: Millendo Therapeutics; Corcept Therapeutics; Janssen Pharmaceuticals; Quest Diagnostics; Novartis; Strongbridge Biopharma; Adrenas Therapeutics; Spruce Biosciences; Selenity Therapeutics.

Linda Barbour, MD, MSPH: Cooperative agreement with Janssen Research and Development, but unrelated to her presentation.

Carolyn B. Becker, MD: Receives royalties from UpToDate.

Anders Carlson, MD: Dr. Carlson’s institution has received research support from Medtronic, Dexcom, Abbott, Novo Nordisk and has received consulting support from Medtronic and Insulet.

James W. Findling, MD: Investigator/Consultant for Corcept, Novartis and Diurnal.

Thomas J. Giordano, MD, PhD: Consultant for Rosetta Genomics.

Ira J. Goldberg, MD: Did consulting in the past year for Amgen, Ionis/Akcea, Pfizer/Regeneron. Received lecture honorarium from Kowa.

Korey Hood, PhD: Receives research support for investigator-initiated project from Dexcom, Inc and receipt of consultant fees from Insulet Corporation, Lilly Innovation Center, Bigfoot Biomedical, and J&J Diabetes Institute.

David Kerr, MBChB, DM, FRCPE: Medical Advisor to Glooko

Shlomo Melmed, MD: Consultant (Consulting Fee): Cliasma, Midatech, Ionis, Strongbridge and Primary Investigator (Research Grant): Pfizer, IPSEN

Mark E. Molitch, MD: Received research support from NovoNordisk, Bayer, Janssen, Chiasma, and Novarits. Consultant for Merck, Pfizer, Ipsen, Chiasma, Novartis, and Janssen.

Michael Rickels, MD: Consultant for Hua Medicine and Xeris Pharmaceuticals.

Henry Rodriguez, MD: A co-investigator on- and his wife receives salary support (as a clinical research coordinator) through a clinical research grant to the University of South Florida from Medtronic. His institution also receives devices from Dexcom for clinical research.

Joshua D. Safer, MD: Spouse is employed by Parexel as a contracts specialist. Was on one advisory panel for Endo Pharmaceuticals in 2018.

Margaret E. Wierman, MD: Grant reviewer for Pfizer, pituitary investigator for grants for NovoNordisk, Corcept, Prolor, Novartis.

Carol Wysham, MD: Consultant/Advisor: Abbott, Janssen, Novo Nordisk, Sanofi. Speakers Bureau: Astra Zeneca, Eli Lilly, Boehringer Ingelheim, Janssen, Novo Nordisk, Sanofi.

The following faculty reported no relevant financial relationships: Bradley D. Anawalt, MD; Shehzad Basaria, MD, MBBS; Kristien Boelaert, MD, PhD; Marc-Andre Cornier, MD; Maria Fleseriu, MD; Megan R. Haymart, MD; Anne E. Kearns, MD, PhD; Susan J. Mandel, MD, MPH; Alvin C. Powers, MD; Janet A. Schlechte, MD; Sharon D. Solomon, MD; Christopher D. Still, DO; Anand Vaidya, MD, MMSc; and Robert A. Wermers, MD

The following faculty will disclose any relevant financial relationships during their presentations: Suzanne M. Jan de Beur, MD and Matthew A. Cavender, MD, MPH.

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.


The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.


The educational content in this self-assessment test relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.


When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.


The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.


The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.


This program is supported by educational grants from AbbVie, Inc., Corcept Therapeutics, Inc., Ipsen Biopharmaceuticals, Medtronic Diabetes, Novo Nordisk Inc., Radius Health, Inc., and TherapeuticsMD.